The publication of the Department of Health’s consultation paper on value based pricing and the ongoing consultation on the Cancer Drugs Fund plus each consultation’s accompanying impact assessment mean that it is now possible to see what is being proposed. This blog looks at the essentials of value based pricing; later blogs will deal with […]